Global Viral Vectors and Plasmid DNA Manufacturing Market Growth (Status and Outlook) 2023-2029

Global Viral Vectors and Plasmid DNA Manufacturing Market Growth (Status and Outlook) 2023-2029

The viral vectors and plasmid DNA is used for the treatment of cancers, inherited disorders, viral infections and other diseases.
LPI (LP Information)' newest research report, the “Viral Vectors and Plasmid DNA Manufacturing Industry Forecast” looks at past sales and reviews total world Viral Vectors and Plasmid DNA Manufacturing sales in 2022, providing a comprehensive analysis by region and market sector of projected Viral Vectors and Plasmid DNA Manufacturing sales for 2023 through 2029. With Viral Vectors and Plasmid DNA Manufacturing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Viral Vectors and Plasmid DNA Manufacturing industry.
This Insight Report provides a comprehensive analysis of the global Viral Vectors and Plasmid DNA Manufacturing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Viral Vectors and Plasmid DNA Manufacturing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Viral Vectors and Plasmid DNA Manufacturing market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Viral Vectors and Plasmid DNA Manufacturing and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Viral Vectors and Plasmid DNA Manufacturing.
The global Viral Vectors and Plasmid DNA Manufacturing market size is projected to grow from US$ 594.8 million in 2022 to US$ 1971.6 million in 2029; it is expected to grow at a CAGR of 18.7% from 2023 to 2029.
Global Viral Vectors and Plasmid DNA Manufacturing key players include BioReliance, Oxford BioMedica, UniQure, Cobra Biologics, etc. Global top four manufacturers hold a share over 45%.
North America is the largest market, with a share about 50%, followed by Asia-Pacific, and Europe, both have a share over 40 percent.
In terms of product, Viral Vectors is the largest segment, with a share about 80%. And in terms of application, the largest application is Cancers, followed by Inherited Disorders, Viral Infections , etc.
This report presents a comprehensive overview, market shares, and growth opportunities of Viral Vectors and Plasmid DNA Manufacturing market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Plasmid DNA
Viral Vectors
Segmentation by application
Cancers
Inherited Disorders
Viral Infections
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
BioReliance
Cobra Biologics
Oxford BioMedica
UniQure
FinVector
MolMed
MassBiologics
Richter-Helm
FUJIFILM Diosynth Biotechnologies
Lonza
Aldevron
Eurogentec
Cell and Gene Therapy Catapult
Biovian
Thermo Fisher Scientific (Brammer Bio)
VGXI
PlasmidFactory

Please note: The report will take approximately 2 business days to prepare and deliver.